Study of imeroprubart for chronic inflammatory demyelinating polyneuropathy (CIDP)
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether a new medicine called imeroprubart can help people with CIDP, a nerve condition causing weakness and numbness. It may provide an alternative to current treatments like steroids or immunoglobulin therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with typical CIDP or certain variants (like multifocal or motor CIDP)
- Currently on stable treatment with steroids or immunoglobulin therapy for at least 3 months
- Have nerve conduction tests supporting CIDP diagnosis
- No history of other nerve diseases (e.g., diabetic neuropathy, hereditary neuropathy)
- Not have poorly controlled diabetes
- No evidence of spinal cord damage or central nervous system demyelination
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This trial tests a new drug called DNTH103 for adults with CIDP, a condition that affects nerves and causes weakness. It aims to see if the drug can help people who are currently on treatment, have tried treatment before, or are new to treatment.
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
Hear when a new Chronic Inflammatory Demyelinating Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.